What is Innate Pharma (IPHA) stock price today?

Innate Pharma (IPHA) currently trades at $1.48 per share. The stock has a market capitalization of $138.87M and a P/E ratio of —x.

Is IPHA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Innate Pharma has a Smart Value Score of 11/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -5.67.

What is Innate Pharma's revenue and earnings?

Innate Pharma has trailing twelve-month (TTM) revenue of $9.01M with profit margins of 0.00%. Earnings per share (EPS) is $-0.64.

Is Innate Pharma financially healthy?

Innate Pharma's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -5.67 places it in the distress.

IPHA

Innate Pharma

NASDAQ: IPHA · HEALTHCARE · BIOTECHNOLOGY

$1.48

+5.71% today

Updated 2026-04-29

Market cap

$138.87M

P/E ratio

—

P/S ratio

15.42x

EPS (TTM)

$-0.64

Dividend yield

—

52W range

$1 – $3

Volume

0.0M

Market cap

$138.87M

P/E ratio

—

P/S ratio

15.42x

EPS (TTM)

$-0.64

Dividend yield

—

52W range

$1 – $3

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.0

Growth

4.0

Quality

2.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-5.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$6.00

+305.41%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -5.67 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-23.48M

- Revenue declining -46.70% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$57.67M	$51.90M	$12.62M	$2.79M	$9.01M
Net income	$-58.10M	$-7.57M	$-49.47M	$-47.24M	$-27.63M
EPS	—	—	—	—	$-0.64
Free cash flow	$-20.28M	$-34.91M	$-7.29M	$-50.81M	$-23.48M
Profit margin	-100.74%	-14.59%	-391.97%	-1,694.87%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
IPHA	$138.87M	11	2.0	2.5	5.0	4.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Innate Pharma trades at $1.48. Our Smart Value Score of 11/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -5.67, it sits in the distress. TTM revenue stands at $9.01M.

Frequently asked questions

What is Innate Pharma's stock price?

Innate Pharma (IPHA) trades at $1.48.

Is Innate Pharma overvalued?

Smart Value Score 11/100 (Grade F, Strong Sell).

What is the price target of Innate Pharma (IPHA)?

The analyst target price is $6.00, representing +305.4% upside from the current price of $1.48.

What is Innate Pharma's revenue?

TTM revenue is $9.01M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-5.67 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.innate-pharma.com

Quick metrics

P/S ratio15.42x

ROE-271.40%

Beta0.75

50D MA$1.49

200D MA$1.83

Shares out0.09B

Float0.07B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

IPHA vs LLY →IPHA vs JNJ →IPHA vs ABBV →Stock screener →